Podcasts
Listen to the latest hemonc news from international experts
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Sequencing BTK inhibitor therapy in CLL: treatment considerations and emerging strategies
This podcast explores sequencing strategies and treatment considerations for BTK inhibitors in chronic lymphocytic leukemia (CLL). Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses treatment options following covalent BTK inhibitor therapy, while Gianluca Gaidano, MD, PhD, University of Eastern Piedmont, Vercelli, Italy, reviews treatment selection, the improved safety of second-generation BTK inhibitors, and the Phase III AMPLIFY trial (NCT03836261) of fixed-duration acalabrutinib plus venetoclax.
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses the CLL-FRAIL study of continuous acalabrutinib in older and frail patients with CLL. Kerry Rogers, MD, The Ohio State University, Columbus, OH, highlights strategies to overcome BTK inhibitor resistance, including fixed-duration combinations and a Phase II study of venetoclax plus ibrutinib in patients with resistance mutations. Finally, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, presents findings from the Phase III BRUIN CLL-322 trial (NCT06073821) evaluating fixed-duration pirtobrutinib, venetoclax, and rituximab in previously treated CLL.
Date: 30th June 2026
